Samsung Biologics207940.KS
本公司簡介的中文翻譯準備中。以下為英文原文。
關於Samsung Biologics
Samsung Biologics is a contract development and manufacturing organization, or CDMO, that produces biologic drugs on behalf of global pharmaceutical companies from large-scale plants in Incheon's Songdo district. The company operates some of the biggest biomanufacturing capacity in the world and earns revenue through long-term production contracts covering antibody-based medicines and related services. It also holds Samsung Bioepis, a biosimilar developer that sells lower-cost versions of off-patent biologic drugs. Samsung C&T and Samsung Electronics are its principal shareholders, placing the company inside the Samsung Group, and capacity expansion has been the main driver of its growth strategy.
Foreign shareholders view the company as a capacity story: contracted orders from multinational drugmakers stretch over multiple years, giving revenue visibility but also concentrating exposure among a limited roster of large pharmaceutical clients. Proposed United States legislation targeting Chinese biotech contractors is watched as a potential structural tailwind for non-Chinese CDMOs. The tight free float, with Samsung C&T holding a controlling position, links the stock to broader Samsung Group ownership arithmetic. The company pays little in dividends, reinvesting cash into new plants, so returns depend on execution of successive expansion phases and biosimilar progress at Samsung Bioepis.
Samsung Biologics was established in 2011 as the Samsung Group's entry into biopharmaceuticals, a deliberate diversification beyond electronics championed by group leadership. The company built its first plant in Incheon's Songdo free economic zone and added successively larger facilities, listing on the Korea Exchange in 2016. Samsung Bioepis, its biosimilar-development arm, began in 2012 as a joint venture with U.S. biotech Biogen and became a wholly owned subsidiary after Samsung Biologics purchased Biogen's stake in 2022. The company weathered a high-profile accounting dispute with Korean regulators over how that venture was valued, an episode that shaped local governance debate.
Contract manufacturing revenue is built on reserved capacity: pharmaceutical clients sign long-dated minimum-volume agreements, often years before production begins, which converts plant construction into a contracted order backlog. Additional income comes from development services, where the company takes client molecules from cell line to commercial process, deepening relationships that later fill manufacturing suites. Scale is the competitive weapon, since larger bioreactor capacity lowers unit costs and lets the company absorb big commercial programs that smaller rivals cannot, positioning it against Lonza, Catalent, and China's WuXi Biologics. Nearly all clients are foreign drugmakers, so contracts are dollar-denominated and export-oriented.
公司簡介由LineVest編輯部撰寫。屬新聞報導，非投資建議。 委託撰寫Samsung Biologics的DART完整報告 →
Samsung Biologics相關報導
17篇文章
Samsung Biologics Q2 2026: Revenue Surges 30% to ₩1.32T, H1 Profit Crosses ₩1.17 Trillion
Samsung Biologics reported Q2 2026 revenue of KRW 1,320.9 billion (+30.2% YoY) and operating profit of KRW 586.4 billion (+22.9%), in-line with market consensus. H1 cumulative revenue reached KRW 2,578 billion with the company tracking the upper end of its 15-20% full-year growth guidance.
Samsung Biologics Bets $2.0 Billion on Swiss Peptide Maker PolyPeptide to Enter the GLP-1 Supply Chain
Samsung Biologics (207940.KS), the Songdo-based contract drug manufacturer within Korea's Samsung group, has agreed to acquire 100% of PolyPeptide Group AG, a Swiss-headquartered contract developer and manufacturer of therapeutic peptides, in the largest M&A ever struck by a Korean pharmaceutical or...
Korea Claims No. 2 FDA Biosimilar Slot as Samsung Biologics' $280M U.S. Plant Anchors Next Growth Phase
Korea holds 19 FDA biosimilar approvals (No. 2 globally). Samsung Biologics completes $280M GSK Rockville acquisition, raising total CDMO capacity to 845,000L. H1 2026 saw 6 new approvals vs 18 in 2025.
Samsung Biologics (207940.KS) Union Quits Group Coalition
Samsung Biologics Unveils Four Drug Delivery Platforms at BIO USA 2026, Targeting Technology Licensing as New Revenue Pillar
Samsung Biologics presented four proprietary drug delivery platforms at BIO USA 2026, signaling a push into technology licensing to diversify revenue beyond contract manufacturing.
Samsung Biologics CEO Reaffirms 15-20% Growth Target at BIO USA 2026, Advances Rockville Ramp and Netherlands Hub
Samsung Biologics CEO John Rim unveiled a three-pillar global expansion at BIO USA 2026: Rockville integration (USD 280M, 60,000L), Netherlands hub (Q3 2026), and Songdo Plant 6 decision by year-end, targeting 1.3 million liters by 2032.
Samsung Biologics Secures KRW 149.1 Billion in CMO Add-Ons as Union Plans Independence Vote
Samsung Biologics disclosed two DART-filed CMO contract expansions totaling KRW 149.1 billion in June 2026, lifting its cumulative backlog to ~USD 10.4 billion, even as the labor union prepares a vote to exit Samsung Group's conglomerate union.
Samsung Biologics Returns to BIO USA for 14th Straight Year, Backed by Record Revenue and a $21 Billion Order Book
Samsung Biologics (207940.KS), the Songdo-based contract drug manufacturer that ranks as the world's largest biopharmaceutical producer by installed c
K-Biotech's Animal-Free Pivot: Samsung Biologics and Peers Race to Meet New FDA and EU Drug Rules
The EU and FDA are converging on a phaseout of animal testing in drug development, creating a new competitive arena where Samsung Biologics and a cohort of Korean biotech firms are building organoid and AI capabilities to stay ahead.
Samsung Biologics (207940.KS) Backs ₩200B Third Bio Fund
Samsung Electronics' ₩600M Bonus Resets the Math for Samsung Biologics Strike Talks
The tentative wage deal that pulled Samsung Electronics — Korea's largest chipmaker — back from an 18-day general strike has handed the still-striking union at Samsung Biologics — Korea's largest cont
Samsung Biologics Wage Impasse Lingers After Electronics' 12% Profit-Share Reset
Samsung Biologics (KRX: 207940), Korea's largest contract drug manufacturer (CDMO), has not yet matched the wage settlement its memory-chip affiliate concluded
Samsung Biologics Pegs Strike Damage at ₩150 Billion ($102 Million) as Labor Unrest Spreads to Kakao
Samsung Biologics Files Criminal Complaint Against Striking Union Chair Over Leaked PR Records
Samsung Biologics (207940.KS) filed a criminal complaint against union chair Park Jae-sung for leaking PR-department tax invoice records and defamation, per Yonha...
Samsung Biologics (207940.KS) Files Criminal Complaint on Strike
Samsung Biologics filed a criminal complaint against six union members, including the branch chair, alleging obstruction during last week's first-ever strike.
Samsung Biologics' First-Ever Strike Halts Cancer-Drug Output, Company Cites ₩150 Billion Loss
Samsung Biologics Partial Strike Extends Into Day Three; Full Walkout Set for May 1
常見問題
What does Samsung Biologics do?
Samsung Biologics manufactures biologic medicines under contract for global pharmaceutical companies, operating some of the world's largest biomanufacturing plants in Incheon, South Korea. It also provides drug-development services and owns Samsung Bioepis, which develops biosimilars, lower-cost versions of off-patent biologic drugs sold in major markets worldwide.
Who controls Samsung Biologics?
Samsung C&T is the largest shareholder, with Samsung Electronics holding another substantial stake, placing the company firmly inside the Samsung Group and its founding Lee family's sphere of control. The free float is comparatively small, and the remaining shares are held by domestic and foreign institutions and retail investors.
How can foreign investors get exposure to Samsung Biologics?
The stock trades on the Korea Exchange under ticker 207940. It has no overseas depositary receipts, so direct ownership requires a broker with Korean market access. Indirect exposure is available through Korea-focused ETFs and some global health-care funds, and partially through shares of its parent, Samsung C&T.
答覆為一般資訊之編輯摘要，非投資建議。
深入標題背後
您剛讀到發生了什麼。接下來，讀懂它意味著什麼。
每天早晨的韓國市場 — 免費
LineVest Daily在首爾開盤前送達您的信箱：KOSPI與KOSDAQ關鍵報導、財報、披露與外資流向 — 以簡明英文呈現。免費，無需信用卡。
Samsung Biologics完整報告
我們完整閱讀Samsung Biologics的最新DART披露 — K-IFRS財務、公司治理，以及對股價的意義。3小時內PDF送達您的信箱。
$12 · 單次
獲取Samsung Biologics報告基於DART原始披露的獨立新聞報導 — 非投資建議。與任何券商無關。